The past 5 years have seen some of the most significant changes in the way we view and treat prostate cancer. 2014 continues in the same spirit and will be remembered as a landmark year for practice changing studies reporting their results in surgery, chemotherapy and novel medical therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management
Clinical Proteomics Open Access 20 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
de Bono, J. S., Logothetis, C. J., & Molina, A. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187–1197 (2012).
Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424–433 (2014).
Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138–148 (2013).
Rathkopf, D. E. et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.02.056.
Ryan, C. J. et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy [abstract 7530]. Ann. Oncol. 25 (Suppl. 4), iv255–iv279 (2014).
Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028–1038 (2014).
Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial [abstract]. J. Clin. Oncol. 32 (Suppl.), LBA2 (2014).
Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370, 932–942 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares that he acts as a consultant and has received research funding from Abbvie, Amgen, Astellas, Janssen, Millennium, and Sanofi.
Rights and permissions
About this article
Cite this article
Saad, F. The year chemotherapy finally gets some respect!. Nat Rev Urol 12, 71–72 (2015). https://doi.org/10.1038/nrurol.2014.362
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.362
This article is cited by
-
Racial/ethnic disparities in survival of metastatic prostate cancer patients treated with external beam radiotherapy
World Journal of Urology (2022)
-
Rural–urban variation in characteristics among prostate cancer patients
World Journal of Urology (2022)
-
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management
Clinical Proteomics (2020)